Document is current

Article History

Received: 4 December 2025

Accepted: 23 March 2026

First Online: 10 April 2026

Declarations

:

: Reis Marques, T. has received honoraria for speaking and chairing from Lundbeck, Janssen, Astellas and Viatris and received honoraria to participate in advisory boards organized by Angelini Pharmaceuticals. He is an employee and shareholder of Pasithea Therapeutics. Dr Mizuno has received consultant fees from Signant Health and WCG Clinical within the past three years. Dr Howes has received research funding from and/or participated in advisory/speaker meetings organised by Abbvie, Alkermes, Angellini, Autifony, Biogen, BMS (Karuna), Boehringer-Ingelheim, Delix, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Jansenn, Karuna, Lundbeck, Merck, Neumora, Neurocrine, Ono, Ontrack/Pangea, Otsuka, Sunovion, Teva, Recordati, Roche, Rovi and Viatris/Mylan. He was previously a part-time employee of Lundbeck A/v. Dr Howes and Dr. Veronese have a patent for the use of dopaminergic imaging. Benedetta Bodini has received compensation for consulting services, speaking honoraria, participation in advisory boards or research support from Genzyme, Merck, Roche, Novartis, and Biogen (to the institution). Bruno Stankoff has received research grants and personal fees for lectures from Roche, Novartis, and Merck-Serono, personal fees for lectures from Alexion, and Janssen. All the other authors do not report any relevant conflict of interest.